Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. LMT
6. RXST
7. SPY
8. SPGI
9. RIVN
10. CMPS

Go back to Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim

TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)

August 4, 2025 2:10 PM EDT

TD Cowen analyst Ritu Baral reiterated a Buy rating and $61.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).

The analyst comments "Our Take: We are highly encouraged by today's data which we believe bodes well for PBO-controlled POWER1 Ph2/3 vormatrigene data due by... More

Praxis Precision Medicines Inc. (PRAX) PT Raised to $33 at Wedbush

August 4, 2025 1:24 PM EDT

Wedbush analyst Laura Chico raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $33.00 (from $28.00) while maintaining a Underperform rating.

The analyst comments "Remain Underperform rated on PRAX, new $33 target. While the headline figure for seizure reduction with vormatrigine represented... More

Praxis Precision Medicines (PRAX) Misses Q2 EPS by 6c

August 4, 2025 9:05 AM EDT

Praxis Precision Medicines (NASDAQ: PRAX) reported Q2 EPS of ($3.31), $0.06 worse than the analyst estimate of ($3.25).

For earnings history and earnings-related data on Praxis Precision Medicines (PRAX) click here.

... More

Praxis reports positive seizure reduction results from vormatrigine trial

August 4, 2025 8:10 AM EDT

Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced results from its Phase 2 RADIANT study of vormatrigine in patients with focal onset seizures. The 8-week study showed a 56.3% median reduction in seizure frequency, according to the company's statement.

Approximately 22% of patients achieved complete seizure elimination during the final 28 days of treatment. More than 54% of patients... More